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ABSTRACT
Background. Downstream activation through receptor
tyrosine kinases (RTKs) plays important roles in carcino-
genesis. In this study, we assessed the clinical involvement
of Axl, an RTK, and its ligand, Gas6, in surgically treated
lung adenocarcinoma.
Methods. Axl and Gas6 mRNA and protein expression
levels were quantified using quantitative real-time poly-
merase chain reaction and immunohistochemistry,
respectively, in completely resected lung adenocarcinoma
tissues (n = 88) and were evaluated for correlation with
clinicopathologic features and patient survival.
Results. Higher expressions of Axl mRNA/protein and
Gas6 protein were significantly related to worse clinico-
pathological features and prognosis (5-year overall survival
rates: Axl mRNA low: 72.3 %, high: 49.7 %, P = 0.047;
Axl protein low: 77.5 %, high: 38.6 %, P \ 0.001; and
Gas6 protein low: 70.5 %, high: 48 %, P = 0.042). On the
contrary, higher Gas6 mRNA expression was related to
better clinicopathological features and prognosis (5-year
overall survival rates: Gas6 mRNA low: 59.2 %, high:
81.8 %, P = 0.054). Multivariate analysis suggests that
high Axl mRNA expression may be an independent factor
for poor patient prognosis (P = 0.04).
Conclusions. In lung adenocarcinoma, Axl and Gas6
expression levels were associated with tumor advancement
and patient survival, thus rendering them as reliable
biomarkers and potential targets for treatment of lung
adenocarcinoma.
Non-small cell lung cancer (NSCLC) has been the leading
cause of cancer-related deaths world-wide, and adenocarci-
noma accounts for about half of all NSCLC cases.1,2 Recent
strategies for cancer treatment have focused on inhibiting
oncogenic pathways in specific cancers. Receptor tyrosine
kinases (RTKs) are some of the most common classes of
molecules investigated for that purpose, and in the treatment
of lung adenocarcinoma, disrupting them with small-mole-
cule RTK inhibitors (TKIs) have already provided us with
new and preferred treatment options.3,4 Unfortunately
though, the targeted patient population and therapeutic
effects are still limited, thus further investigation on RTKs is
vital to provide more therapeutic alternatives.
Recently, the TAM family of RTKs has been reported to
regulate various biological processes.5 This family consists
of Tyro3 and Mer as well as Axl.6 Axl has already been
reported to be overexpressed in several human cancers.7–11
Its natural ligand, Gas6, binds Axl with three- to tenfold
higher affinity than Mer and causes Axl phosphorylation,
which results in activation of various downstream path-
ways.12,13 Thus, Axl/Gas6 signaling contributes to a
variety of oncogenic mechanisms.14,15
Although some reports have already mentioned the
expression or effects of Axl in lung cancer, specific or
detailed clinical impact of both Axl and Gas6 expression
have not, thus far, been fully investigated.16,17
In this study, we retrospectively evaluated Axl and Gas6
expression levels in lung adenocarcinoma at both the
genetic and protein levels, confirming their role in carci-
nogenesis, which we believe will be useful clinical
reference in utilizing these molecules as cancer biomarkers
and future therapeutic targets for the treatment of lung
cancer.
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MATERIALS AND METHODS
Patients, Tissue Samples, and Tumor Information
Tissue samples were obtained from patients who had
undergone complete surgical resection of primary lung
adenocarcinoma without any prior anticancer therapies at
Kyoto University Hospital between 2001 and 2005
(n = 88). All of these tumors were histologically con-
firmed as lung adenocarcinoma, and their lymph node (LN)
metastatic status, pathological (p-) staging, degree of dif-
ferentiation, and pleural/vascular/lymphatic invasion status
were all assessed by board-certified pathologists in the
Department of Pathology of Kyoto University Hospital.
P-stage was determined by the latest tumor-node-metasta-
sis classification system.18 Histological type and grade of
cell differentiation were determined according to the WHO
classification system.19 EGFR gene mutations (exons
18-21) were detected using polymerase chain reaction
(PCR) single-strand conformational polymorphism analy-
sis, and K-ras gene mutations (codon 12) were screened
using the mutagenic PCR restriction enzyme fragment
length polymorphism method.20 Informed consent for
participation in this study was obtained from all patients
before their surgeries, and this study was reviewed and
approved by the Ethics Committee of the Graduate School
and Faculty of Medicine at Kyoto University.
Preparation of Tissue mRNA
For sample collection, tumor tissue samples were dis-
sected immediately after surgical resection and soaked in
RNAlater TissueProtect Tubes (Qiagen, Tokyo, Japan) for
more than 48 h before storage at -80 C until use. Total
RNA was isolated from tissue samples using RNeasy Plus
Mini Kit (Qiagen), and reverse transcription of total RNA
was conducted using the Ready-To-Go You-Prime First-
Strand Beads (Amersham Biosciences, Uppsala, Sweden)
to obtain cDNA.
Quantification and Evaluation of Axl and Gas6 mRNA
To quantify Axl and Gas6 mRNA expression levels of each
sample, quantitative real-time PCR was performed using the
LightCycler thermal cycler system (Roche Diagnostics Japan,
Tokyo, Japan). The PCR primers used for the quantitative
amplification of Axl mRNA were forward: 50-GGTGGCTGT
GAAGACGATGA-30 and reverse: 50-CTCAGATACTC
CATGCCACT-30, and those of Gas6 mRNA were forward:
50-ACATCTTGCCGTGCGTGCCCTTCA-30 and reverse:
50-ATTCCGCGCCAGCTCCTCAACAGA-30. The primers
for glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
mRNA, used as an internal control, were forward: 50-ACA-
ACAGCCTCAAGATCATCAG-30 and reverse: 50-TCTTCT
GGGTGGCAGTGATG-30. After a 20-lL reaction mixture
containing 0.5 lM forward and reverse primers and 0.03 lg
cDNA in QuantiTect SYBR Green PCR Master Mix (Qiagen)
was prepared, PCR amplification was initiated by preincu-
bation for 15 min at 95 C for initial activation, followed by
40 cycles of the following protocol: denaturation at 94 C for
15 s (sec), annealing at 59 C for 15 s, and elongation at
72 C for 15 s with detection of fluorescence products. The
quantitative data were analyzed with LightCycler analysis
software version 5.03 (Roche Diagnostics Japan). The
expression levels of Axl and Gas6 were represented as the ratio
of Axl or Gas6 mRNA value to GAPDH mRNA value. The
patients were dichotomized on the basis of the mean value of
Axl or Gas6 mRNA expression, and their clinicopathologic
features and survival curves were later analyzed.
Immunohistochemistry of Axl and Gas6
Immunohistochemical (IHC) staining was performed
using Dako LSAB ? System-HRP (Dako Japan, Tokyo,
Japan). Formalin-fixed, paraffin-embedded tissue was cut
into 4-lm sections and mounted on glass slides. After
deparaffinization and rehydration, the slides were heated in
a buffer solution (HistoVT One, Nacalai Tesque, Kyoto,
Japan) for antigen retrieval at 90 C for 20 min. After
quenching the endogenous activity with 0.3 % hydrogen
peroxide (in absolute methanol) for 10 min, the sections
were treated with blocking agent (DAKOCytomation Pro-
tein Block, Dako Japan) for 30 min to block nonspecific
staining. The sections were incubated overnight with a
rabbit anti-Axl polyclonal antibody (sc-20741, 1:100, Santa
Cruz Biotechnology, Inc., CA, USA) or a goat anti-human
polyclonal Gas6 antibody (AF885, 1:100, R&D Systems
Inc., MN, USA). The slides were then incubated for 50 min
each with the secondary antibody (Biotinylated Link, Dako
Japan) and peroxidase (STREPTOAVIDIN-HRP, Dako
Japan), followed by visualization with 3,30-diaminobenzine
tetrahydrochloride (DAB ? CHROMOGEN, Dako Japan).
Finally, the sections were counterstained with Mayer’s
hematoxylin (Dako REAL Hematoxylin, Dako Japan). The
negative control slides were prepared by replacing the
primary antibody with an irrelevant mouse immunoglobu-
lin G (N1698, Dako Japan).
Evaluation of IHC Results
Axl and Gas6 protein expression were estimated
according to a semiquantitative scoring system, in which
the staining intensity was graded as 0 (no staining), 1
(weak), 2 (moderate), or 3 (strong), and percentage of
positive cells was graded as 0 (negative), 1 (B10 %), 2
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(11–50 %), 3 (51–80 %), or 4 ([80 %). The final IHC
score was obtained by multiplication of both grading
results (staining intensity 9 percentage of positive cells).
The IHC scores were compared within each clinical cate-
gory, and the clinicopathological features and survival
curves were analyzed after dichotomization according to
their staining intensity (each IHC score: B7 vs. [7).
Statistical Analysis
Statistically significant differences within categorical
data were determined using the v2 test. Continuous data of
two groups were compared using Student’s t test and that
of three or more groups were compared using ANOVA.
Survival curves were evaluated with the Kaplan–Meier
method, and cumulative survival data were compared using
the log-rank test. Multivariate analysis of prognostic fac-
tors was performed by the Cox proportional hazard model.
Differences were considered significant when P \ 0.05.
mRNA expression levels and IHC scores are expressed as
median and mean ± standard deviation. All statistical
analyses were performed using StatMate IV software ver-
sion 4.01 (ATMS, Tokyo, Japan) and JMP software version
8 (SAS Institute Japan, Tokyo, Japan).
RESULTS
Axl and Gas6 mRNA Expression Correlated well
with Clinical Variables
The level of Axl mRNA (normalized and expressed as a
ratio to GAPDH mRNA) ranged from 0 to 8.77 9 10-3
(8.37 9 10-4, 1.39 9 10-3 ± 1.62 9 10-3), and that of
Gas6 mRNA ranged from 1.26 9 10-4 to 2.11 9 10-1
(7.59 9 10-3, 1.37 9 10-2 ± 2.68 9 10-2). Sixty patients
were placed in the Axl mRNA low group and 28 patients in
the high group, whereas 66 patients were placed in the
Gas6 mRNA low group and 22 patients in the high group
(below versus above each mean value; Table 1).
FIG. 1 High Axl mRNA and
low Gas6 mRNA expressions in
lung adenocarcinoma tissue
correlated with poorer patient
survival. Kaplan–Meier curves
for overall (a, c) and disease-
free (b, d) survivals according
to Axl (a, b) and Gas6
(c, d) mRNA expression levels.
P values were calculated by the
log-rank test. Ticks censored
cases
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FIG. 2 a Immunohistochemical
staining analysis of lung
adenocarcinoma tissue for Axl (top)
and Gas6 (bottom), showing cases
with negative, weak, moderate, and
strong staining patterns. Scale bar
20 lm. b Axl immunoreactivity
increased according to tumor
differentiation, pathological (p-)
stage, maximum tumor size, lymph
node (LN) metastatic status, and
serum tumor marker levels in lung
adenocarcinoma tissue at time of
resection. c Gas6 immunoreactivity
also correlated well with LN
metastatic status. CEA
carcinoembryonic antigen; SLX
sialyl Lewis X-i antigen. P values
were calculated by Student’s t test or
ANOVA
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A statistically significant correlation was found between
pleural invasion status and Axl mRNA expression. Gas6
mRNA expression was significantly associated with tumor
differentiation, p-stage, maximum tumor size, LN meta-
static status, lymphatic invasion status, and EGFR gene
mutation status, which unexpectedly showed that the high
Gas6 mRNA expression group included more patients with
better clinicopathological features.
Axl and Gas6 mRNA Expression Reflected
Postoperative Patient Survival
Five-year overall survival (5y-OS) rates in the Axl
mRNA low and high groups were 72.3 and 49.7 %,
respectively, which was statistically significant
(P = 0.047; hazard ratio (HR) = 0.5; 95 % confidence
interval (CI), 0.21–0.99; Fig. 1a). Five-year, disease-free
survival (5y-DFS) rates in the Axl mRNA low and high
groups were 58.9 % and 39.3 %, respectively (P = 0.094;
Fig. 1b).
Similarly, the 5y-OS rates in the Gas6 mRNA low and
high groups were 59.2 and 81.8 %, respectively
(P = 0.054; Fig. 1c). The 5y-DFS rates in the Gas6 mRNA
low and high groups were statistically different at 45.5 and
72.7 %, respectively, and surprisingly, log-rank testing
revealed significantly better patient DFS in the Gas6
mRNA high group (P = 0.028; HR = 2.5; 95 % CI,
1.1–5.7; Fig. 1d).
Axl and Gas6 Protein Expression also Correlated well
with Clinical Variables
The IHC score for Axl ranged from 0 to 12 (7,
6.3 ± 3.3) and that of Gas6 ranged from 2 to 15 (6,
6.3 ± 2.8). Representative images of Axl and Gas6 IHC
at each staining intensity level are presented in Fig. 2a.
Statistically significant associations were found between
Axl IHC score and tumor differentiation, p-stage, maxi-
mum tumor size, LN metastatic status, and serum tumor





for overall (a, c) and disease-
free (b, d) survivals according
to Axl (a, b) and Gas6
(c, d) immunohistochemical
(IHC) scores. P values were
calculated by the log-rank test.
Ticks censored cases
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marker levels (Fig. 2b), as well as between Gas6 IHC
score and LN metastatic status (Fig. 2c).
Fifty-nine and 29 patients were placed in the Axl IHC
low and high groups, respectively, whereas 66 and 22
patients were included in the Gas6 IHC low and high
groups, respectively (each IHC score: B7 vs. [7;
Table 1).
Statistically significant differences were found between
the Axl IHC low and high groups with regard to age,
gender, p-stage, and LN metastatic status, and between the
Gas6 IHC low and high groups with respect to maximum
tumor size and LN metastatic status.
Axl and Gas6 Protein Expression Predicted Patient
Survival
The 5y-OS rates in the Axl IHC low and high groups
were 77.5 and 38.6 %, respectively, which is statistically
significant (P \ 0.001; HR = 0.31; 95 % CI, 0.11–0.54;
Fig. 3a). There also was a statistical difference in the
5y-DFS rates between the Axl IHC low and high groups at
65.7 and 24.7 %, respectively (P \ 0.001; HR = 0.33;
95 % CI, 0.12–0.49; Fig. 3b).
Similarly, the 5y-OS rates in the Gas6 IHC low and high
groups were 70.5 and 48 %, respectively (P = 0.042;
TABLE 2 Univariate and multivariate analyses of Axl mRNA expression and other clinicopathological variables for patient survival
Variables Univariate analysis (OS) Univariate analysis (DFS) Multivariate analysis (OS)
Hazard ratio 95 % CI P* Hazard ratio 95 % CI P* Hazard ratio 95 % CI P
Axl mRNA expression
Low 1 0.047 1 0.094 1 0.04
High 2 1.01–4.8 1.7 0.91–3.5 1.9 1.03–3.5
Age (yr)
\65 1 0.47 1 0.75 1 0.2
C65 0.77 0.38–1.6 0.91 0.5–1.7 0.71 0.43–1.2
Gender
Male 1 0.0045 1 0.087 1 0.99
Female 0.3 0.17–0.73 0.57 0.32–1.08 1 0.43–2.1
Smoking status
Never smoked 1 0.0026 1 0.051 1 0.37
Smoker (ex or current) 4.3 1.5–6.4 2 1–3.5 0.68 0.28–1.6
Tumor differentiation
Well 1 1 1
Moderately 4.5 1.4–9.8 0.01 2.6 1.2–5.2 0.012 1.3 0.73–2.2 0.39
Poorly 11.8 5–38.7 \0.001 4 2–11.8 \0.001 3 1.4–6.4 0.004
P-stage
I 1 1 1
II 0.55 0.12–3.1 0.56 1.3 0.41–4.6 0.6 0.63 0.22–1.5 0.33
III 5.9 4.6–26 \0.001 5.3 5.3–26.7 \0.001 2.1 1.1–4.1 0.022
Adjuvant chemotherapy
No 1 1 1
Yes 0.51 0.2–1.04 0.061 0.62 0.29–1.2 0.14 0.45 0.25–0.8 0.0067
EGFR gene mutation status
Wild-type 1 0.0077 1 0.29 1 1
Mutation (?) 0.35 0.19–0.77 0.72 0.39–1.3 1 0.54–1.9
K-ras gene mutation status
Wild-type 1 0.23 1 0.12 1 0.63
Mutation (?) 0.49 0.23–1.4 0.46 0.25–1.2 1.2 0.55–2.6
Bold values are statistically significant
OS overall survival; DFS disease-free survival; CI confidence interval
* Log-rank test
 Cox’s proportional hazard model
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HR = 0.48; 95 % CI, 0.17–0.97; Fig. 3c). The 5y-DFS
rates in the Gas6 IHC low and high groups were 58.4 and
34.5 %, respectively, with statistical significance as well
(P = 0.035; HR = 0.53; 95 % CI, 0.21–0.95; Fig. 3d).
High Axl mRNA Expression may be an Independent
Factor of Poor Prognosis in Surgically Treated Lung
Adenocarcinomas
The results of the univariate analyses for each clinico-
pathological parameter and the multivariate analyses are
presented in Table 2. We found that high Axl mRNA
expression may be an independent factor for poor patient
prognosis in lung adenocarcinoma (P = 0.04; HR = 1.9;
95 % CI, 1.03–3.5).
DISCUSSION
In a previous report, Wimmel et al.16 analyzed Axl and
Gas6 expression in NSCLC and small cell lung cancer
(SCLC) cell lines, and Shieh et al.17 reported correlations
of Axl protein expression with LN involvement and clini-
cal stage. Our findings on the impact of Axl expression on
patient survival further corroborated these observations.
Furthermore, our study is the first to identify Axl mRNA
expression as a possible independent factor on clinical
outcomes in lung adenocarcinoma.
In this report, we found that pleural invasiveness was
specifically related to higher Axl mRNA expression, sug-
gesting its pivotal role in tumor invasion, as revealed by
Tai et al.21 Factors, such as p-stage and LN metastatic
status, also were shown to be statistically associated with
Axl protein expression, which is consistent with its
essential role in epithelial-to-mesenchymal transition.22
The independency of EGFR gene mutation in relation to
Axl expression also was revealed, which is surprising
considering the possible cross-talk or alternative activation
between Axl and EGFR.23,24 K-ras gene mutation, which is
another important mutational pattern in NSCLC, also was
found not to be correlated with either Axl or Gas6
expression level.25 Higher tumor Gas6 protein expression
was shown to be related to not only advanced tumor status
but poorer patient survival, suggesting its significance in
tumor advancement.11
In contrast to these results, it was intriguingly shown
that genetic expression of Gas6 had an opposite tendency
than that of Axl and Gas6 protein expression. Irrespective
of the fact that Gas6-dependent Axl phosphorylation results
in subsequent activation of oncogenic pathways,26
Cormack et al. 27 revealed that increased Gas6 mRNA
expression was associated with favorable prognostic fac-
tors in breast cancer, and this phenomenon was also found
in RCC.10 All of these aforementioned results seen in other
types of tumors are concordant with the findings of our
present study. Although the precise mechanism underlying
this expression inconsistency has yet to be elucidated, it is
postulated that while Gas6 mRNA is naturally of tumor
origin, Gas6 protein as detected by IHC is generally
exogenous. It is already known that Gas6 is expressed not
only by tumor cells but also by endothelial cells, fibro-
blasts, vascular smooth muscle cells, and infiltrating
immune cells,28 and tumor cells are stimulated via para-
crine as well as autocrine fashion by Gas6, which also is
found in serum.10 It also is assumed that paracrine-derived
Gas6 incorporation into tumor cells represses tumoral Gas6
expression per se, resulting in downregulation of Gas6
mRNA expression. We hope that further investigations will
clarify the underlying mechanisms.
In light of the limited therapeutic options currently
available for NSCLC, the Axl/Gas6 system remains an
attractive therapeutic target,29 and some small molecules
with Axl inhibitory effects are already under develop-
ment.30 Elucidation of the exact mechanisms of Gas6
stimulation on tumor tissue (i.e., autocrine and/or para-
crine) would increase the efficacy of targeting this RTK
axis for the treatment of lung adenocarcinoma.
In conclusion, we found that Axl and Gas6 were highly
expressed in surgically treated lung adenocarcinoma tis-
sues at both genetic and protein levels, revealing their
marked correlations with clinical outcomes. We believe
that our findings contribute to further understanding of
these promising molecules in utilizing them as novel bio-
markers and therapeutic targets in NSCLC.
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